American Century Companies Inc. Buys 175,570 Shares of LivaNova PLC $LIVN

American Century Companies Inc. raised its stake in LivaNova PLC (NASDAQ:LIVN) by 31.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 726,950 shares of the company’s stock after buying an additional 175,570 shares during the period. American Century Companies Inc. owned 1.33% of LivaNova worth $38,078,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of LIVN. Artisan Partners Limited Partnership boosted its stake in shares of LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after purchasing an additional 1,179,436 shares during the last quarter. Invesco Ltd. raised its stake in LivaNova by 714.7% during the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after buying an additional 902,447 shares during the last quarter. Scopia Capital Management LP acquired a new position in LivaNova in the second quarter valued at $36,657,000. AQR Capital Management LLC boosted its position in shares of LivaNova by 30.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock valued at $92,201,000 after purchasing an additional 478,525 shares in the last quarter. Finally, M&G PLC bought a new stake in shares of LivaNova during the 2nd quarter valued at about $11,762,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

LIVN has been the subject of several research analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $66.00 price target on shares of LivaNova in a research note on Friday, January 9th. Piper Sandler reiterated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. KeyCorp began coverage on shares of LivaNova in a report on Friday, December 19th. They issued an “overweight” rating and a $81.00 target price on the stock. Robert W. Baird set a $75.00 target price on LivaNova in a report on Tuesday, December 16th. Finally, Mizuho increased their target price on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Stock Performance

NASDAQ:LIVN opened at $63.84 on Friday. The business has a 50 day moving average price of $65.08 and a 200-day moving average price of $59.51. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $71.92. The firm has a market cap of $3.49 billion, a PE ratio of -14.31 and a beta of 0.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.16 and a current ratio of 1.36.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.86 million during the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities research analysts predict that LivaNova PLC will post 2.85 earnings per share for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.